Skip to main content
Journals

Ultrasound-Assisted Facial Autologous Fat Grafting: A Systematic Review of Perioperative Safety and Volumetric Outcomes

Aesthetic Surgery Journal
Aesthetic Surgery Journal

Authors: Ronghao Ouyang, MD , Ximeng Jia, MD , Ziming Zhang, MD , Yutong Liang, MD , Benjie Li, MD , Mengzhe Qin, MD , Jintian Hu, MD, PhD

Abstract: High-frequency ultrasound (HFUS) is increasingly used to map facial vasculature and tissue planes, identify prior fillers, and objectively assess volume after autologous facial fat grafting (AFG), but its perioperative benefit has not been systematically synthesized. We performed a PRISMA-compliant systematic review (PROSPERO registration: CRD420251242117), searching PubMed, Embase, Web of Science Core Collection, and the Cochrane Library from inception to November 1, 2025 without language restrictions. We included human clinical studies using B-mode and/or Doppler ultrasound preoperatively, intraoperatively, or postoperatively and reporting safety and/or volumetric outcomes. Methodological quality was assessed using National Institutes of Health tools; due to heterogeneity, findings were narratively synthesized. Twelve studies (885 patients; 2017-2024) were included, predominantly single-center observational designs. Across studies, HFUS supported vascular mapping and filler characterization, real-time confirmation of cannula location within intended planes (“safe layers”), and postoperative monitoring of retention and complications. In a comparative temple augmentation cohort, ultrasound guidance enabled higher injection volumes (22.32 ± 5.19 vs 10.55 ± 2.25 mL) and higher satisfaction (92% vs 74%) without increased complications. Ultrasound-measured retention typically declined during the first 3 to 6 months and then stabilized, with approximately 50% to 70% retention at 1 year and higher retention after supplementary grafting (49.4% vs 71.7% in one cohort). No study reported blindness, stroke, or skin necrosis; adverse events were generally mild and transient. Overall, HFUS-assisted facial AFG appears promising for risk stratification and objective monitoring, but higher-quality comparative studies with standardized ultrasound protocols and core outcome sets are needed.

JOURNAL ARTICLE

Related Articles

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for inducing weight loss has increased in recent years, resulting in a parallel reduction in demand for bariatric surgery. Consequently, the need for patients to undergo aesthetic procedures, including aesthetic breast surgery, following successful GLP-1 RA–induced weight loss is expected to increase while the demand created by postsurgical weight loss is expected to decrease. The objective of this narrative review is to examine the literature on the use of GLP-1 RAs and other mechanisms used for medical weight loss to assist plastic surgeons in achieving optimal aesthetic outcomes with breast surgery after weight loss occurs.
Hyaluronic acid (HA) is widely used for lip augmentation; however, the safety and performance of injection techniques and instruments (needle vs cannula) remain unclear. The aim of this study was to evaluate the safety of HA injection techniques for lip augmentation and to assess patient satisfaction, injected volume, and associations with technique, instrument, and HA product.
Resident-run clinics (RRCs) have become an important component of plastic surgery training. This study evaluates outcomes from a longitudinal RRC focused on neuromodulator and soft tissue filler injections over a 5-year period. The aim of this study was to assess clinical outcomes, patient retention, resident experience by postgraduate year (PGY) level, and the safety of RRCs as a training model.
Poly-L-lactic acid (PLLA) is a biostimulatory injectable that restores midfacial volume through collagen neogenesis rather than gel-based filling. Controlled clinical evidence directly quantifying PLLA's volumetric efficacy remains limited. This study aimed to evaluate the efficacy, safety, and patient-reported outcomes of a Norberg Medical PLLA formulation for midface rejuvenation in a prospective, evaluator-blinded, split-face controlled study.
Botulinum neurotoxin A (BoNT-A) is widely used clinically; yet, its temporary effects require repeated injections that increase cost and inconvenience. There is limited rigorous evidence to support claims that repeated BoNT-A use alters efficacy. Unlike peripheral nerve transection, which causes irreversible denervation after 12 to 24 months, the long-term physiological effects of BoNT-A chemodenervation remain unclear.